---
title: "BioNTech initiates the first Phase III clinical trial of B7-H3 ADC, expected to obtain results in January 2031"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273812231.md"
description: "BioNTech has initiated the first Phase III clinical trial of DB-1311/BNT324, expected to recruit 736 participants, with results to be announced in January 2031. BNT324 is a B7-H3 ADC developed by DUALITYBIO, which was licensed to BioNTech in April 2023, granting the latter development, production, and commercialization rights outside of China"
datetime: "2026-01-27T08:23:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273812231.md)
  - [en](https://longbridge.com/en/news/273812231.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273812231.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273812231.md) | [English](https://longbridge.com/en/news/273812231.md)


# BioNTech initiates the first Phase III clinical trial of B7-H3 ADC, expected to obtain results in January 2031

The U.S. ClinicalTrials.gov website shows that BioNTech has launched the first Phase III clinical trial of DB-1311/BNT324, expected to recruit 736 participants, with results anticipated in January 2031.

BNT324 is a B7-H3 ADC developed by DUALITYBIO (09606.HK), which was licensed to BioNTech in April 2023. The company holds the rights for the development, production, and commercialization of the drug outside of China

### 相關股票

- [BioNTech SE (BNTX.US)](https://longbridge.com/zh-HK/quote/BNTX.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [DUALITYBIO-B (09606.HK)](https://longbridge.com/zh-HK/quote/09606.HK.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Sutro Biopharma (STRO.US)](https://longbridge.com/zh-HK/quote/STRO.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [Direxion S&P Biotech Bear 3X (LABD.US)](https://longbridge.com/zh-HK/quote/LABD.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)

## 相關資訊與研究

- [BioNTech Co-Founders to Launch Independent mRNA Venture as Company Refocuses on Late-Stage Pipeline](https://longbridge.com/zh-HK/news/278540977.md)
- [Deutsche Bank  Keeps Their Buy Rating on BioNTech SE (BNTX)](https://longbridge.com/zh-HK/news/278570303.md)
- [BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update | BNTX Stock News](https://longbridge.com/zh-HK/news/278538839.md)
- [Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data](https://longbridge.com/zh-HK/news/278566951.md)
- [Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis](https://longbridge.com/zh-HK/news/278448836.md)